nektar sweet initi market perform
updat content see later public
note follow initi public document made factual correct name chang mechan bempegaldesleukin nktr-
alpha partial alpha molecular weight assumpt molar calcul
pleas refer disclosur appendix analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
contact svb leerink editori depart descript benchmark avail contact svb leerink
approach mont carlo simul entir immuno-
risk dynam consid
probabl technic
probabl disrupt outcom
correl outcom everi
treatment mechanist class
develop path poc trial
probabl mont carlo simul
probabl technic
note use discount rate compani given simul revenu stream alreadi consid mani risk typic account higher discount rate
mp valuat risk
initi coverag market perform rate price driven larg view bempegaldesleukin
believ likelihood failur bempeg higher typic given sub-optim dose decis clinic de-risk
signal yet reach bar proof-of-concept poc said scale aggress
parallel registr program io-respons tumor type hedg risk
nktr/bmi develop strategi launch competit tumor set multipl io therapi alreadi avail
mani other pipelin believ bempeg nivo level transform activ take signific share
option
partnership term deal good increas price target pay major develop cost
bempeg nivo retain profit
earli pipelin see upsid valu pegyl agonist bempeg program combin
potenti colder tumor like tnbc high risk success tumor offer upsid driver valu model
also believ pegyl hedg risk back-up bempeg
see import catalyst next six month
could send neg signal give exclus indic yet registr trial june deadlin
announc work addit indic announc intent
cohort data nsclc tnbc fulli recruit data updat present
announc present emso end septemb
opinion base inform public domain extens convers medacorp kol despit repeat attempt
compani manag meet us
project revenu deriv mont carlo simul rang outcom part entir io industri pipelin
valuat price target base dcf analysi simul revenu bempeg plu platform
sale pegyl product royalti take account net cash hand sg overhead cost
nsclc and/or tnbc cohort posit meet poc bar
bempeg nivo prove transform set better chemo
set high bar tumor like melanoma rcc nsclc
sever clinical-stag program util smart pharmacolog platform
found
list
bempegaldesleukin partner
combin nivolumab
numer indic collabor
takeda vaccibodi
pegyl
bempeg r/r melanoma
pain pdufa date
august potenti advisori
meet expect earli august
timelin key near-term catalyst
data studi bempeg nivo
ad com pdufa august
updat melanoma data bempeg
first clinic data healthi
expir exclus
data bempeg nivo tnbc sept
data bempeg nivo nsclc esmo
data bempeg nivo rcc ikcc
view debat
bempeg nivo
support data
potenti
believ signal promis
question wisdom pursu multipl
registr trial parallel rather
de-risk smaller
bempeg low dose limit efficaci
lack single-ag respons
neg signal given other
class activ
bempeg nivo cohort
met proof-of-concept bar
look next
addit cohort data
nsclc tnbc
definit signal
opt
indic
scientif hypothesi preclin
addit clinic data
evid promis
data close relat competitor look
data sting
stronger either preclin
evid poor translat sting
oncolyt viru
face system barrier
hamper sale recent
emphas risk abus
deterr properti payer
unwilling pay premium price
fda feedback label
payer physician
valu late-stag io pipelin royalti stream
stream
product
stream
product
ionian immuno-oncolog industri analyt note yet give valu preclin program clinic program without human data bempeg
combin assum overhead result return equal discount rate give valu onzeald fail metastat breast cancer mbc
nektar price target upsid downsid scenario
program
use
issu larg impact
percentil mont
bempeg prove
competitor limit
partial alpha alpha
alpha activ
percentil mont
averag bempeg ptr probabl disrupt efficaci score score score score note yet give valu preclin program
clinic program without human data bempeg combin assum overhead result return equal discount rate give valu onzeald fail
base consensu
platform
use smart pharmacolog platform build pipelin
develop asset royalti stream
smart pharmacolog platform util polym chemistri control pharmacokinet bio-
distribut receptor select high precis
target well-character bio-molecular pathway like therapeut benefit
exploit structur malleabl polym tune behavior new molecul
platform gener new pegyl asset either wholli own co-develop
well royalti stream numer out-licens product
revenu manufactur ip licens continu
declin relev collabor late life-cycl stage
gener revenu fix price manufactur well royalti
expect revenu sourc slowli declin come year
collabor matur state
signific partner program includ adynov factor viii replac
challeng newer drug like hemlibra well gene therapi movantik pill oic
face competit faster act relistor
built substanti develop pipelin bempegaldesleukin
cancer import valu
plan
nda file anticip pdufa aug
on-going trial subpopul broader
combo nivolumab
combo nivolumab
combo nivolumab acceler approv path single-arm
combo nivolumab post cpi expans
cohort w/ potenti acceler approv support on-going
combo
combo avelumab
combo avelumab talazoparib
parp enzalutamid anti-androgen
combo neo-antigen vaccin
fap inhibitor cpi
lead indic sle
combo bempegaldesleukin
fda delay pdufa asset indic includ sum-of-part valuat fail metastat breast cancer mbc give valu asset though on-going trial
mbc stabl brain metastas announc intent begin registr trial sclc tnbc colorect gastric and/or sarcoma virolog indic collabor
adapt compani report
nktr io pipelin score best
iob index medacorp kol gave highest score bempeg cpi
score mechan part
iob object assess
biolog clinic evid
mechan asset
coverag import io
expect asset move toward
right get clinic evid
single-ag combin
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
cytokin involv prime activ step cancer
overcom short half-lif toxic wild-typ aldesleukin
made bempeg ad polym attenu bind
illustr bempegaldesleukin bind
bempegaldesleukin green six addit site red
bempegaldesleukin pegyl
mediat partial alpha interact
yield control sustain
control clinic impact avoid cell
sustain exposur half-lif extens
remov bia treg
polym incorpor non-select
six lysin bempeg-aldesleukin prodrug
four lysin hydrolyz creat
activ partial alpha
though skeptic bempeg lack single-ag activ low dose
signal combo nivo promis enough move random trial
synergi
presenc dlt indic
bempeg human dose limit efficaci
read evid
aldesleukin
nk cell popul
lack singl
nivo combo
note order magnitud
dose continu
dose differ
single-ag studi size
small make conclus
expect respons rate
given aldesleukin
single-ag respons bempeg
respons neg
activ seen pd marker
drug without activ alon
nk total lymphocyt well ae
surrog grade chill pyrexia
consist delta alon
ppt orr ppt cr
three cohort strong posit signal
object respons rate seen patient
low til express would
expect alon
melanoma bladder pd-
patient convert
associ respons
rare ever add benefit
nk pd marker
cohort met object bar io
alon set anti-
activ random data
provid clariti
small trial often mislead
known adapt immun
marker patient respond
increas express pd-
includ
data bempeg nivo promis though believ poc reach
question nsclc tnbc data releas
earli stage clinic signal cohort expans
enrol
nsclc five patient releas despit patient across
half r/r enrol expect data esmo
tnbc result releas despit patient enrol
expect data cri-cimt-eati-aacr septemb
present -gu antoni riba novel strategi augment efficaci immunotherapi
critic watch sever signal refin posit
bempegaldesleukin potenti
want see
definit signal move forward
company-sponsor trial post
addit indic jcpd sclc
clinicaltri gov updat allow delay
and/or confirm plan end
nsclc i-o r/r cohort
minimum orr higher better
updat nsclc i-o nave cohort
orr delta nivo alon
tnbc i-o nave cohort
orr delta nivo alon
updat rcc i-o nave cohort
improv orr
combin
bempegaldesleukin
innat immun cell activ involv first two step
immun cell cycl
use pegyl keep small molecul agonist
inject tumor increas durat agon reduc system ae risk
illustr pegyl
data show intratumor retent
unconjug agonist vs
bempeg earli clinic patient see
posit neg signal watch come data report
strength
evid
impact innat
adapt immun well character
synergi activ innat
adapt bempeg
immun system local distal tumor
abscop effect seen mice studi
like real given pegyl
ad bempeg nivo
reduc variabl immun system
health tme distant metastas
therebi support abscop activ
broader set patient
translat innat immun find
mice human particularli poor
sting type interferon agonist
shown stronger preclin activ
abscop effect seen mice result
diffus non-inject
human abscop effect
variabl tme distant metastas
immun system health
bempeg /- nivolumab
overcom tme challeng alon
strength
therapeut index like larg despit
slow releas could differenti
mice human signal type ifn
agonist bell-shap dose
curv could difficult
pegyl complic kinet
though trial size small
shown promis activ
io combin
small trial often mislead
singl agent
activ sting agonist
azn discontinu agonist
though trial size small patient sever tlr agonist
includ shown promis activ io combin
earli stage clinic orr signal tlr agonist
pembro melanoma
pembro scchn
pembro
r/r melanoma orr
azn announc discontinu
agonist
tilsotolimod ipilimumab r/r
across tumor type orr
present -sitc dynavax present esmo scchn esmo
idera corpor present antoni riba novel strategi augment efficaci immunotherapi
recent opioid abus deterr product commerci success
reason believ differ
believ sale hamper
fda label emphas risk abus deterr properti
box warn languag like embeda expos user risk addict
abus misus lead overdos death assess patient risk
prescrib monitor regularli behavior condit
embeda formul sequest opioid antagonist naltrexon hcl
releas manipul crush buri label
payer unwilling pay premium price abus deterr patient combin
lack valid method select patient suscept addict abus
barrier system believ face challeng
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc fda iqvia
annual current cash account current non-curr long-term properti equip lt total liabil stockhold total current account accru expens defer revenu short term debt- non-current senior secur note royalti defer revenue less lt total stockhold prefer stock- common capit excess par accumul accumul statement
annual net non-cash royalti revenu relat sale futur non-cash interest expens liabil relat sale futur defer depreci stock base oper cash balanc incl current market securitiesbegin end
nektar leadership extens drug develop pharma experi
presid chief execut offic
introduct
cytokin involv prime activ step cancer
attract therapeut target fuel immune-medi kill
cancer cell induc teffector nk cell prolifer cytotox
stimulatori impact innat adapt immun cell
increas prolifer activ t-cell natur killer nk cell
induc differenti cell effector teff effector memori tmem t-cell
enhanc product cytotox protein granzym involv anti-tumor respons
sim gc radvanyi cy gf review
use cancer patient requir navig
role immun toler
role counter product treat cancer patient
increas prolifer inhibitori regulatori cell treg lower dose
requir immun stimul
pleotrop immun stimulatori suppress role exist parallel cytokin act local
differenti express receptor subunit enabl immun system use
activ effector respons respons high local concentr
limit overstimul autoimmun tempor treg stimul activation-induc cell
death well spatial peripher tissu sop excess infect edg
sim gc radvanyi cy gf review
clinic high-dos recombin requir immun
stimul cur use limit sever on-target toxic
aldesleukin two on-label
long durat low
respons aldesleukin
approv metastat rcc
melanoma
dinutuximab
combin gm-csf
isotretinoin aldesleukin
approv pediatr
label vivo high dose
necessari stimul effect
howev across indic
high dose requir efficaci
ug/kg lead sever
toxic limit use
hand academ center
durat respons
month
month
month
nausea vomit
month
month
month
mrcc mmelanoma patient
low-dos stimul treg high toxic reduc half-lif wt
mediat bind bind suffici immun stimul
counter-product role mediat ci tran increas receptor
affin mediat signal
mainten expans suppress
continu expans differenti low
teff nk transient
toxic includ vascular leak syndrom vl
eosinophilia high level
reduc half-lif receptor intern
bind subunit suffici signal immun stimul nk cell
high level bind alon activ
innat adapt immun expans cytotox prime
engag high level therapeut impact less clear
next-gener demonstr toler human trial
though expect bempeg would look like aldesleukin higher dose
alpha fuse tumor-target
aldesleukin dose result sever seriou advers effect requir constant monitor
though alpha molecul trae medacorp kol concern
hypotens problem predict hydrat alpha
outpati sure tabl captur aldesleukin need icu continu
monitor hydrat concomit drug even tabl
valid human hypothesi relat vascular leak syndrom vl primarili
associ cytokin bind present lung epitheli innat lymphoid cell
full account see appendix dose escal continu mg/kg pharmacodynam marker suggest efficaci dose yet reach
believ next gen may provid synergist benefit numer io
gen cytokin capac rapidli increas prolifer activ
specif immun cell t- nk-cell
speed kinet respons tumor cpi on-set biolog
function slow tumor cpi fail improv like rcc
activ nk cell overcom cpi resist downregul
monoclon
activ nk cell increas toxic mabs-medi tumor
support engraft cell therapi adopt cell therapi use aldesleukin
complement innat immun system activ antigen present cell
subsequ gener antigen specif t-cell
speed kinet respons enabl notori slow cancer
vaccin benefit metastat patient faster grow tumor
expect data rhhbi well updat
 collabor import catalyst year
preliminari data readout atezo
complet studi adcc antibodi
updat data bempeg nivo nsclc
updat data bempeg nivo tnbc
updat data bempeg nivo rcc
initi registr trial bempeg cpi rcc
uc nsclc nsclc
thor initi undisclos cpi
anticip earli highlight initi clinic trial wherea late
mark clinic trial data rhhbi potenti
overcom short half-lif toxic wild-typ aldesleukin
made bempeg ad polym attenu bind
illustr bempegaldesleukin bind
bempegaldesleukin green six addit site red
bempegaldesleukin pegyl
mediat partial alpha interact
yield control sustain
control clinic impact avoid cell
sustain exposur half-lif extens
remov bia treg
polym incorpor non-select
six lysin bempeg-aldesleukin prodrug
four lysin hydrolyz creat
activ partial alpha
though skeptic bempeg lack single-ag activ low dose
signal combo nivo promis enough move random trial
synergi
presenc dlt indic
bempeg human dose limit efficaci
read evid
aldesleukin
nk cell popul
lack singl
nivo combo
note order magnitud
dose continu
dose differ
single-ag studi size
small make conclus
expect respons rate
given aldesleukin
single-ag respons bempeg
respons neg
activ seen pd marker
drug without activ alon
nk total lymphocyt well ae
surrog grade chill pyrexia
consist delta alon
ppt orr ppt cr
three cohort strong posit signal
object respons rate seen patient
low til express would
expect alon
melanoma bladder pd-
patient convert
associ respons
rare ever add benefit
nk pd marker
cohort met object bar io
alon set anti-
activ random data
provid clariti
small trial often mislead
known adapt immun
marker patient respond
increas express pd-
includ
partnership good deal major mileston come
june could forfeit exclus tumor type
feb announc joint clinic develop plan jcdp
total up-front payment mileston
up-front cash payment up-front equiti invest
elig addit develop regulatori mileston well
book revenu world-wide sale keep major global profit
major develop cost broad registration-en trial opdivo
opdivo yervoy paid annual develop share cap
free develop bempegaldesleukin anti-canc agent intern third parti
gain access resourc infrastructur expedit broad develop program
start middl
registration-en clinic trial indic nine tumor type patient
three indic on-going registr trial melanoma rcc urotheli cancer
one specif registr plan announc nsclc
next set registr trial design implement sclc tnbc
colorect gastric sarcoma
exclus fall provis state studi defin indic jcdp start within
month effect date collabor subject allow delay indic longer
subject exclus believ may opt addit indic
announc intent deadlin approach shortli
nektar bristol-my squibb collabor agreement feb present
dose threshold like critic efficaci believ bempeg human
dose sub-efficaci limit toxic wild-typ peg hydrolyz
sustain exposur longer
half-lif like benefit
molecul achiev
dose otherwis
extend half-lif littl valu
top figur laid
relev cell
bempegaldesleukin dose
limit toxic cpi
combin ug kg lead
ug/kg expans
dose limit efficaci
lower molar aldesleukin
molar mice dose
ac cmax near
relev cell
nk cell
popul ac
less potent
assumpt molecul mw bempeg weight averag ac speci base murin kinet ac
hour rang base murine-human report antibodi kda averag person liter blood kg nhp
ml blood volum murin kg ml blood volum compar vitro activ human mice ac activ
compon bempeg
poster klein et al oncoimmunolog measur express human t-cell compar activ
neg cell data shown roch poster
clinic advanc next-gen bempegaldesleukin
singl activ
alpha superagonist increas affin
alpha fuse tumor-target mab
mg mg/kg
demonstr yet partial alpha improv clinic activ
clinic respons give proof mechan alpha
bempegaldesleukin respons either metastat rcc melanoma
major caveat studi small number patient one medacorp kol reflect
 use aldesleukin five year never saw respons
patient would expect see respons
dose escal continu mg/kg phamacodynam marker suggest efficaci dose yet reach
pd marker bempegaldesleukin shown dose-respons
demonstr dose sensit
dose respons human immun prolifer marker percentag peripher blood
administr bempeg increas treg popul increas popul
nk-cell correl popul absolut cell count unclear
dose respons human immun cell count peripher blood
dose increas absolut cell count nk-cell increas dose
minim alter treg popul follow dose
dose escal mg/kg underway
object interpret result single-arm combin trial oncolog
follow riba propos
threshold requir posit earli stage signal
set
low activ orr
anti-
r/r anti-
set
ppt delta orr
orr similar combo partner alon
unaccept toxic pazopanib
random os need demonstr combin
synergist sequenc may prefer given
antoni riba novel strategi augment efficaci immunotherapi
data bempeg nivo promis though believ poc
reach question nsclc tnbc data releas
earli stage clinic signal cohort expans
enrol
nsclc five patient releas despit patient across
half r/r enrol expect data esmo
tnbc result releas despit patient enrol
expect data cri-cimt-eati-aacr septemb
present -gu antoni riba novel strategi augment efficaci immunotherapi
see margin signal bempeg nivo melanoma result
random data necessari path would prudent
appli object single-arm combin threshold delta ppt popul readili respond
nivolumab alon poor signal cusp promis signal rang
agre deserv explor random trial question prudenc move directli
larg phase random studi
bempeg nivo signal urotheli cancer uc promis
delta ppt orr though still poc combin
uc cisplatin
appli object single-arm combin threshold
delta ppt overal patient readili respond alon promis
delta ppt low patient might consid proof-of-concept combo inde
set pursu acceler approv howev small patient popul
refus chemo vs pembro trial cisplatin inelig reduc confid signal
also concern patient select bia given investig dr note
enrol patient across trial r/r trial
bempeg nivo signal rcc promis requir
random data call poc
appli object single-arm combin
threshold delta ppt popul
readili respond nivolumab alon promis
agre deserv explor
figur data present motzer rj et al nejm registr trial mrcc
convers data mislead secondari patient
biopsi show spontan convers checkpoint inhibitor alon
human data show convers
bempegaldesleukin nivolumab
chen et al data pair biopsi data melanoma patient
treat blockad alon
melanoma urotheli carcinoma patient convert bempegaldesleukin
nivolumab convert neg tumor posit associ respons
known adapt immun marker patient respond alon increas express
includ neg posit shown evid chen et al right
small patient number clear whether bempegaldesleukin increas convers
nivolumab could patient popul
addit rhhbi nektar human pd biomark data encourag
inconclus
chang peripher
treatment increas peripher nk- t-cell without effect treg
demonstr clinic benefit peripher pd data modest tumor pd data
present bodi design go away homeostasi difficult see chang peripher
blood im interest expans tumor clinic medacorp kol reaction data
chang
bempeg treatment lead highli variabl increas number tumor infiltr lymphocyt
suspect bar chart increas cell driven almost entir patient
medacorp kol reaction data hard tell difficult interpret variabl data would expect
alway see expans blood densiti tumor go keep lot
trial patient dont think help
bempegaldesleukin pharmacokinet pk profil complic due
hydrolysi linker gener activ speci
aldesleukin rapidli clear hour requir continu dose
pk profil next gener molecul vari depend therapeut modal like
complic intern
bempegaldesleukin extend pk profil hour
kinet profil molecul complic non-linear hydrolysi chain
requir activ speci bempegaldesleukin-ac
thor molecul singl decay profil due homogen gener non-hydrolys
rhhbi longest day may also ada
requir repeat dose hour due small size rapid clearanc
bempegaldesleukin-rc pegyl speci bempegaldesleukin-ac activ speci compris free
bempeg increas treg ratio find interpret limit dose
differ mice human nktr use ratio vs absolut cell count
singl dose bempeg mg/kg significantli increas treg ratio tumor microenviron compar
aldesleukin mg/kg bid two cycl alon left two figur
use data suggest bempeg caus treg leav tumor could act immuno-protect
ira skeptic argument
though ratio vs cell count make difficult absolut interpret til indic increas drive
ratio tumor treg deplet
medacorp kol comment data
impress expans teff treg effect believ treg go
tumor spleen ratio driven teff
treg effect clear human suspici evid treg
stimul expand
academ lab combin bempeg mg/kg act mice show similar treg ratio
tumor also show treg decreas lymphocyt spleen right figur
nektar poster parisi et al note mice underw lymphodeplet prior bempeg act dose
appendix comparison
sever compani develop similar next gener alpha
form overcom toxic short half-lif treg prefer aldesleukin
logic modal
compani asset
partial
interact il-
occlud
alpha fuse tumor-
reduc toxic associ
bind high-affin receptor
elimin preferenti activ
treg teff nk cell
increas tumor concentr
follow target bind antibodi
antigen expand activ teff
nk cell tumor microenviron
reduc toxic associ
system deliveri fusion still
peripher blood
enhanc bind increas
activ expans teff
reduc toxic due preferenti
bind receptor lack
roch rhhbi
highli competit landscap next-gen
alpha super agonist increas affin
alpha fuse tumor-target mab
efficaci
next-
launch
fuse
sourc compani report devoid fc-mediat effector function
chang titl partial
though bempeg lead clinic believ
promis next-gener
alpha super agonist increas affin
alpha fuse tumor-target
next gener demonstr single-ag clinic
orr along favor safeti pk profil
count dose respons also uniqu grade short half-lif requir
preclin asset non-human primat data show
molecul well dose extend biolog half-lif
believ bempeg dose toler limit clinic singl agent
though may show efficaci mani on-going combin studi low dose like
preclin limit data avail
elicit anti-drug like obscur clinic activ like
low prioriti molecul rhhbi activ clinic
outsid random clinic data level confid alpha
molecul base eight attribut
attribut like requir clinic success
manag toxic efficaci dose
close gap teff treg activ
cell nk cell exhaust
confid score
broad
retain bind affin signal wt
produc high number persist cytotoxic-prim teff
nk cell teff antigen-specif tumor
local concentr activ tumor microenviron
show synergist effect combin cancer
though earli promis
profil across attribut like requir success
alpha super agonist increas affin
alpha fuse tumor-target
disclos neg signal mix hard interpret signal
note score increas preclin human data
single-ag activ combo nivo compar favor nivo alon nivo ipi high anti-drug antibodi report
may limit clinic effect half-lif hour dose poster dose escal continu phamacodynam marker suggest efficaci dose yet reach
appendix
combin
innat immun cell activ involv first two step
immun cell cycl
use pegyl keep small molecul agonist
inject tumor increas durat agon reduc system ae risk
illustr pegyl
data show intratumor retent
unconjug agonist vs
bempeg earli clinic patient see
posit neg signal watch come data report
strength
evid
impact innat
adapt immun well character
synergi activ innat
adapt bempeg
immun system local distal tumor
abscop effect seen mice studi
like real given pegyl
ad bempeg nivo
reduc variabl immun system
health tme distant metastas
therebi support abscop activ
broader set patient
translat innat immun find
mice human particularli poor
sting type interferon agonist
shown stronger preclin activ
abscop effect seen mice result
diffus non-inject
human abscop effect
variabl tme distant metastas
immun system health
bempeg /- nivolumab
overcom tme challeng alon
strength
therapeut index like larg despit
slow releas could differenti
mice human signal type ifn
agonist bell-shap dose
curv could difficult
pegyl complic kinet
though trial size small
shown promis activ
io combin
small trial often mislead
singl agent
activ sting agonist
azn discontinu agonist
pegyl agonist design safe induc antigen
present chemokin releas lead t- nk-cell tumor clearanc
illustr agonist impact alon combin bempegaldesleukin
upon ssrna recognit lead product type interferon chemokin stimul
innat adapt immun inject tumor
matur tumor-resid dendrit cell present cancer antigen prime cell
cell differenti effector teff effector memori t-cell increas product cytotox
protein granzym traffic tumor
tumor microenviron tme chang support cell tumor kill
meaning clinic outcom like requir local impact propag distal metastas abscop
effect traffick prime teff/tem cell
human abscop effect rare observ inconsist medacorp kol note
promis earli data oncolyt viru trial
hurdl may includ immunosuppress tme lack chemokin signal distal metastas well
poor overal immun system health
believ ad bempeg nivolumab help overcom hurdl believ sound
hypothesi unclear whether cocktail suffici
encourag pre-clin data medacorp expert caution
translat innat stimul mice human poor
pre-clin data
increas amount
dendrit cell present tumor
tumor drain lymph node
activ innat nktr-
adapt bempeg
immun system local
distal tumor
translat mice
human particularli poor
activ type interferon
stimul unexplor
 could
agonist similar sting agonist mice
singl agent less effect sting
agonist murin tumor model
sting agonist murin top bottom tumor model
agonist murin tumor model
innat immun cell activ tlr- sting agonist bind differ receptor
respect signal pathway converg increas product type interferon
compar data murin tumor model
singl agent tlr agonist minim abil elicit tumor clearanc requir
combin activ
sting effect singl agent inject tumor need checkpoint combin
abscop efficaci distant tumor
agonist lead clinic two on-going random trial
combin lead agonist
sourc compani report potenti random data releas registr trial decis complet enrol
though trial size small patient sever tlr agonist
includ shown promis activ io combin
earli stage clinic orr signal tlr agonist
pembro melanoma
pembro scchn
pembro
r/r melanoma orr
azn announc discontinu
agonist
tilsotolimod ipilimumab r/r
across tumor type orr
present -sitc dynavax present esmo scchn esmo
idera corpor present antoni riba novel strategi augment efficaci immunotherapi
encourag see type interferon increas
wonder bi-mod patient respons suggest patient select approach
increas fold follow monotherapi treatment
respons seem bimod patient either respond remain
baselin wonder whether subset patient respond could
posit neg depend abil prospect select respond patient
granzym ifn- gene modestli upregul follow treatment
bempegaldesleukin broadli increas associ gene
present asco-sitc
cancer immun cycl
cytokin involv prime activ
attract therapeut target compar activ
without associ cytotox immun suppress
interleukin stimulatori impact innat adapt immun cell
increas prolifer activ t-cell natur killer nk cell
induc differenti cell effector teff effector memori tmem t-cell
enhanc product cytotox protein granzym involv anti-tumor
unlik increas prolifer inhibitori regulatori cell treg caus
activation-induc cell death biolog limit
sim gc radvanyi cy gf review
cautious optimist pre-clin data need
detail program compar molecul clinic
pre-clin data
increas prolifer activ
nk- t-cell show pathway engag
synergi adcc enabl antibodi
consist activ nk-cell
extend half-lif compar
alpha similar
without dose limit bempeg hedg
major risk bempeg failur
sever caveat remain
singl agent activ limit
efficaci tumor clearanc
limit toxic data avail nhp
expect enter clinic
recent opioid abus deterr product commerci success
reason believ differ
believ sale hamper
fda label emphas risk abus deterr properti
box warn languag like embeda expos user risk addict
abus misus lead overdos death assess patient
risk prescrib monitor regularli behavior condit
embeda formul sequest opioid antagonist naltrexon
hcl releas manipul crush buri label
payer unwilling pay premium price abus deterr patient combin
lack valid method select patient suscept addict
barrier system believ face challeng
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc fda iqvia
iqvia sale erdaiichi sankyonot launchedtarginiq erpurduenot launch pegyl version oxycodon pre-clin
pre-clin data
bind mu-opioid receptor moder
rel low penetr compar
nhp habit format
compar opioid
clinic data patient treat
report reduct pre-
treatment pain score compar
poster annual frontier clinic investig symposium poster societi neurosci annual meet poster american
associ nurs practition nektar poster american societi anesthesiologist
delay dampen like score pupil diamet
believ abus deterr overdos protect
pegyl oxycodon design abus deterr altern due
pegyl reduc blood-brain barrier cross low high dose
delay dampen euphor respons compar oxycodon
physiochem properti stabil reveal known chemic
enzymat physic method hydrolyz deconjug otherwis produc known
abus opioid enabl rapid entri patient abus crush chew
tablet swallow
think fda may concern dampen impact stronger subject
mean like score object chang pupil diamet
face lot competit pain drug late stage
develop six abuse-deterr opioid
pain product current phase stage
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc biomedtrack
productindicationmechan actioncurr painsodium channel nsaidndaheronloteprednol pain and/or inflammationcorticosteroidndabausch health painnsaidndarecro back painopioidndanektaroxycodon erchron painopioidndaintellipharmaceuticsxaracollpostsurg painsodium channel ndainnocollampionosteoarthr painhuman serum painosteoclast inhibitoriiiaxsomebrixadichron back painopioidiiibraeburncebranopadolcanc painopioidiiigrnenthalcingalosteoarthr painviscosuppl pain clbpopioidiiiegaletfasinumaboa pain clbpngfiiiregeneron/tevahydexormoder sever painopioid acetaminophen antiemeticiiicharleston labsinvossaosteoarthr paingen therapi tissuegeneiv tramadolpostsurg painopioidiiiavenu therapeuticskorsuvapostsurg back painstem cell therapyiiimesoblastnerixiachron painbisphosphonateiiiabiogen pharmaoliceridineacut painopioidiiitrevenaoxycodon hcl iracut painopioidiiipmrsposidurpostsurg painsodium channel iiidurectremoxychron painopioidiiipain pain and/or inflammationcorticosteroidiiisparcsequestoxmoder sever painopioidiiielit paincorticosteroidiiisemnur pharmatanezumaboa pain clbpngfiiipfizer/lillyzalvisochron back painopioidiiiacelrx compet declin market feder agenc state legislatur
take step curb prescript opioid use
volum narcot analges dispens
rx opioid usag
mme
declin
notabl
mme
rx opioid usag increas pill per american adult
pill declin pill
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc iqvia medicin use spend
review outlook april
though fda encourag industri develop new opioid
gener version harder manipul
fda encourag develop new innov
drug abus deterr profil
fda also interest broaden use abuse-
fda issu guidanc requir abus
deterr label
guidanc industri abuse-deterr opioid
evalu label final guidanc explain
fda current think studi
conduct demonstr given formul
fda also look broaden use abuse-
deterr formul adf gener
current gener opioid fda-
fda guidanc develop gener abus
deterr gener oral solid opioid focus
tier-bas approach test base complex
difficulti effort releas opioid drug
evalu abus deterr specif
potenti rout abus
identifi effect manipul condit
test refer product prior
sampl select physic manipul
conduct compar vitro studi
compar test refer product extract
studi assess vulner product
statist comparison test refer product
guidanc essenti abuse-deterr opioid
approv
ami fadia svb leerink pain high unmet need area pipelin still meager want fda guidanc fda
iob framework object evalu breakthrough
potenti io pipelin mechan asset
score mechan part
iob object assess
biolog clinic evid
mechan asset
coverag import io
biolog evid io space
increasingli import earli stage
signal combin often
sourc svb leerink io team judgement base review literatur compani present svb leerink proprietari survey medacorp immunologist immuno-oncologist februari
previous use clinic howev toxic limit applic
treatment bempegaldesleukin overcom dose limit toxic
surviv benefit singl agent activ combin checkpoint inhibitor
sever physiolog relev murin model
ratio percentag cell report prolifer marker
activ marker granzym measur rna express
safeti nhp human
reduc capac bind bind compar natur
extend half-lif complic hydrolysi pd profil demonstr
increas prolifer peripher immun cell
dose limit due
clinic data avail
clinic data avail
approv path like tradit design allow combin checkpoint inhibitor
like requir collabor
nr bempegaldesleukin singl agent pursu
total score calcul base weight averag criteria score biolog rational anim model immun cell biolog structure/funct activ criteria
reduc score improv score pk/pd safeti
total score calcul base weight averag criteria score single-arm evid random evid identifi respond popul criteria
reduc score improv score regul risk clinic hurdl
iob evalu criteria evalu single-ag treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiologically-relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
iob evalu criteria evalu combin treatment
clariti role cancer immun abil bia activ
desir pleiotropic/context-depend mechan
evid surviv benefit physiologically-relev murin
evid impact absolut immun cell count antigen-
specif activ state prolifer marker vitro kill
potenti immun cell isol anim post dose
specif strength target bind
extend benefit evidenc dot bonu long tail
evid dot synergi
extent clinic impact standard-of-car bonu long tail
eas identifi respond patient popul base orr
contribut part
evid synergi base increment orr vs backbon
presenc pd marker practic half-lif deliveri
width therapeut window
depend novel un-valid outcom trial design
level unmet medic need given current standard care
criteria asset score
score multipli weight risk score neg impact
given lack random data io score weight non-random data plan shift weight time random data emerg
acronymdefinitionacronymdefinitionactadopt t-cell therapymibcmuscl bladder canceractadopt cell therapymnsclcmetastat non small cell lung cancerada anti-drug antibodymss-crcmicro-satellit stabl colorect cancer adccantibody-depend cellular cytotoxicityndanew drug applicationaicdactiv induc cell deathnhpnon-human primateblabiolog licens applicationnrnuclear receptorceacarcinoembryon antigennsclcnon small cell lung cancercpischeckpoint inhibitorsoicopioid induc constipationcrpccastration-resist prostat canceroomord magnitudedcrdiseas control rateorrobject respons ratedltdose-limit toxicitiespdpharmacodynamicsdordur cell death protein therapypegpolyethylen maxim effect concentrationpfsprogression-fre survivalfapfibroblast activ proteinpkpharmacokineticsfcfrag crystalliz regionpocproof tumor base vaccin technic regulatori successgm-csfgranulocyte-macrophag colony-stimul factorrccren cell carcinomaicuintens unitssccsquam cell carcinomaifninterferonscchnsquam cell carcinoma head glutamic-oxaloacet transaminaseindinvestig new drugstingstimul interferon genesindsinvestig new drug submissiontiltumor infiltr lymphocytesioimmuno-oncolog tlrstoll like receptorsiobeimmuno-oncolog breakthrough evaluationtmetumor microenvironmentionianimmuno-oncolog industri analysticstraetreat relat advers eventipintraperitonealuculc colitisiraesimmun relat advers eventsucurotheli carcinomajcdpjoint clinic develop planvegfvascular endotheli growth factormabmonoclon antibodyvegf rvascular endotheli growth factor receptormbcmetastat breast cancervlsvascular leak syndromemcrcmetastat colorect cancerwbcwhit blood cellsmcrpcmetastat castrat resist prostat cancerwwworldwid disclosur
